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Background: Glypican-3 (GPC3) is a heparan-sulfate proteoglycan frequently expressed on the cell membrane of
malignant hepatocytes in hepatocellular carcinoma. The capacity for screening potential antibodies in vitro using human
hepatocellular lines is critical to ensure binding to this highly post-translationally modified glycophosphatidylinositiol-
linked protein. We hypothesized that we could utilize a recently described paired display/secretory yeast library to isolate
human-derived scFv against glypican-3 for potential diagnostic and/or therapeutic application.
Results: Using two different biotinylated antigen targets, a synthesized 29mer fragment GPC3550-558 and a truncated
GPC3368-548 fused with glutathione S-transferase (GST) we enriched the yeast display library to greater than 30% target-
specific yeast with both positive selection and depletion of streptavidin- and GST-specific clones. After cloning of scFv
cDNA from the enriched sub-library, scFv specificity was validated by ELISA for binding to recombinant protein from
prokaryotic and eukaryotic sources and ultimately naturally presented human protein on the cell membrane of human
hepatocellular cell lines. Specificity was confirmed using non-expressing cell lines and shRNA knockdown. Ultimately, five
unique scFv with affinity EC50 ranging from 5.0-110.9nM were identified.
Conclusions: Using a paired display/secretory yeast library, five novel and unique scFvs for potential humoral or chimeric
therapeutic development in human hepatocellular carcinoma were isolated and characterized.Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third most common cause of cancer-
related death worldwide [1]. During transformation from
dysplastic regenerating hepatocytes to malignant hepa-
toma cells, several tumor-associated proteins are expressed
that potentially could allow immune discrimination of
malignant hepatocytes from surrounding non-tumor cells.
Glypican-3 (GPC3), an oncofetal antigen re-expressed in a
high frequency of neoplastic hepatocytes [2-5] has
emerged as a useful immunohistochemical diagnostic test
[6-8] and potential biomarker [3,9,10] for hepatocellular
carcinoma. Glypican-3 appears critical for the association
of growth factors such as insulin-like growth factor-2,
bone morphogenic protein-7 and fibroblast growth factor-2
with growth factor receptors [11,12] but also may play an
immunomodulatory role [13]. Inhibition of glypican-3* Correspondence: dakaplan@mail.med.upenn.edu
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a profound negative effect on HCC cell line proliferation.
Unlike any other tumor antigen associated with hepatocel-
lular carcinoma, GPC3 is a glycophosphatidylinositiol-
linked membrane-associated protein with a large extracel-
lular domain attractive for antibody-directed therapy.
An anti-glypican-3 murine IgG antibody that induces
antibody-dependent cytotoxicity has been shown to have
anti-tumor effect in a xenograft animal model of hepato-
cellular carcinoma [17] but required partial humanization
before entering human clinical trials [18]. Thus, while
there is a strong rationale for targeting glypican-3 for
humoral and potentially chimeric immunotherapy for
HCC, an scFv of human origin might be less immunogenic
and more flexible for incorporation into downstream
applications.
A paired yeast display/secretory scFv library derived from
immunoglobulin heavy and light chains originally derived
from the B-cells of a human patient with thrombotic throm-
bocytopenic purpura [19] has been shown to be a powerful
tool for the identification of human scFv against surface-
expressed human tumor antigens [20]. Key advantages ofhis is an Open Access article distributed under the terms of the Creative Commons
/licenses/by/2.0),whichpermitsunrestricteduse,distribution,andreproductioninany
.
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heavy and light chain pairings, efficient flow cytometric en-
richment, eukaryotic-type post-translational modifications,
absence of potential xenoreactive sequences and efficient
conversion to soluble secreted scFv for validation [20].
In this study, we report our development and validation
of multiple human glypican-3-specific scFv. The high
throughput methodology identified human-derived scFv
with EC50 ranging from 5.0 – 110.9nM. These scFv bound
specifically to glypican-3-expressing cell lines. scFv binding
was significantly reduced by shRNA knockdown of
glypican-3. We believe these scFv are optimal for develop-
ment for diagnostic and in vivo therapeutic applications.Figure 1 Target antigens applied to screen yeast display
library. A. Schematic diagram of the primary structure of two
antigen approaches selected from hGPC3 protein. The 29mer
hGPC3530-558 peptide and truncated hGPC3 fused with GST are
represented by gray regions. Two glycosaminoglycan binding site
(Gag) and putative glycosylphosphatidyl-inositol (GPI) anchor regions
within the C-terminal hydrophobic region of hGPC3 are shown. B.
SDS-PAGE gel stained with Coomassie brilliant blue showing the
expressed GST-fusion protein. BL21 bacteria transformed with the
plasmid pGEX-4T/GPC3, encoding a GST-human/mouse GPC3 fusion
protein, were induced to express the recombinant protein in
presence of IPTG. Recombinant proteins were purified by
glutathione agarose beads. The purified proteins (10 ul/each) were
electrophoresed on a 10% SDS-PAGE gel for analysis. C.
Confirmation of the purified recombinant protein by western blot.
The purified recombinant protein were subjected to 10% SDS-PAGE
and transferred to a nitrocellulose filter. The filter was probed with a
commercial monoclonal anti-human GPC3 antibody (clone 1G12).
Note the cross-reactivity of murine GPC3 with 1G12 antibody.Results
Preparation of target antigen for screening of hGPC3-
specific scFv
Two target antigens were developed for scFv isolation. First,
to specifically target the region between two C-terminal
GAG modification sites and the hydrophobic putative
GPI-linkage domain predicted by an online algorithm
(http://tools.immuneepitope.org) [21,22], we chose a 29mer
peptide hGPC3530-558 for commercially synthesis in
biotinylated and non-biotinylated formats (Figure 1A);
however, only a single VH-only scFv labeled G3-C1 was
obtained using this peptide approach. Therefore, we
expressed and purified a larger truncated hGPC3368-548-
GST fusion protein spanning a larger region of the
C-terminus of the protein (Figure 1B). Purity of the
expressed fusion protein was further confirmed by Western
blot with the 1G12 mAb. (Figure 1C). Both the 29mer
hGPC3530-558 and hGPC3368-548-GST were biotinylated for
yeast library screening.Isolation of hGPC3-reactive scFv-displaying yeast
The yeast library was subjected to two rounds of magnetic-
sorting using biotinylated hGPC3530-558 or three rounds of
magnetic-sorting using biotinylated hGPC3368-548-GST to
enrich hGPC3-specific scFv-expressing yeast. The third
magnetic sort of hGPC3368-548-GST was a depletion sort
to eliminate GST-specific scFv-expressing yeast using
biotinylated GST. The enriched sub-library was then
further enriched for hGPC3-specific scFv-expressing yeast
with three rounds of flow sorting selecting for yeast
expressing scFv-c-myc and biotinylated antigen at progres-
sively decreasing concentration (Figure 2A). Streptavidin-
PE was used to identify scFv specific for biotinylated target
in the first two rounds. Neutravidin-PE was utilized in the
third round to eliminate selection of streptavidin-specific
scFv-expressing yeast (~9% of yeast after MACS and two
rounds of FACS sorting). This strategy yielded a marked
enrichment of hGPC3-reactive yeast to approximately 30%
of the population (Figure 2B).Selection of hGPC3-specific scFvs by ELISA
The majority of yeast clones obtained after transduction of
scFv cDNA cloned into a secretory plasmid produced scFv
at detectable quantities in supernatant (Figure 3A).
Approximately 300 transformed yeast colonies were sub-
cultured for high-throughput Ni-purification of super-
natant. These 300 scFv candidates were then assessed
for binding to rhGPC3 by ELISA (Figure 3B). In order to
eliminate GST-reactive scFv, each scFv candidate was
tested in parallel for binding to both GST and rhGPC3-
GST. Thirty-six scFv candidates with ODhGPC3-GST/ODGST
ratios greater than 1.5 were selected for further screening
(Figure 3B). By then testing binding to full-length glycosy-
lated recombinant hGPC3 protein expressed in a murine
myeloma cell line by ELISA (Figure 3C), we identified thir-
teen candidates with ODGPC3/ODmedia ratio greater than 2.
Biological characterization of the scFv candidates
Among these thirteen scFvs candidates, eight yeast colonies
with varying ELISA affinity were chosen for further valid-
ation. Soluble scFvs were purified from the supernatant by
Figure 2 Enrichment of hGPC3-reactive scFvs. A. Surface co-localization of hGPC3-reactive yeast cells after two rounds of MACS-sorting. Yeast
display library were incubated with target antigens and MACS sorting were performed. hGPC3-reactive yeast are double-labeled with mouse anti-c-myc
detected with anti-mouse Alexa Fluor 488 (green) secondary and biotinylated hGPC3-GST detected by streptavidin-phycoerythrin (red). B. Successful
enrichment of hGPC3-reactive yeast cells by three rounds of FACS sorting. Representative FACS sorting using 29mer peptide hGPC3530-558 antigen was
shown. Gradually decreasing concentrations of antigen were utilized in each round. Yeast cells without antigen incubation were used as control. In third
FACS sorting, the PE-conjugated neutravidin was used in order to minimize enrichment of streptavidin-specific scFv also present in the library.
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antibody/liter of culture. By dot blot analysis, all scFv
recognized rhGPC3 protein with no cross-reactivity with
GST protein (Figure 4A), confirming ELISA findings. Nu-
cleotide sequencing of these thirteen scFv yeast colonies
revealed five unique sequences, for which 2E10, 3E11, 3D8,
4G5, and 2G9 represented one of each clone. The analysis
of the predicted amino acid sequence by alignment of
scFv heavy and light chain variable region sequence to aFigure 3 Validation of scFv specificity by ELISA. A. Preparation of solub
co-transformed into YVH10 yeast using p416-BCCR vector. Yeast were induc
loaded into SDS-PAGE gel for detection by anti-V5 mAb in Western Blot. Ap
ELISA screening of 576 scFv for binding to hGPC3-GST. Maxsorb plates wer
plates then washed extensively. HRP-conjugated anti-V5 mAb was used for
to hGPC3-GST and GST. C. scFv with highest hGPC3-GST/GST binding ratio
mammalian cells by ELISA. G3-C1 is a VH only scFv isolated using GPC3530-5
GST fusion protein.database of human immunoglobulin germline sequences
(V base directory of human V gene sequences) using
IgBLAST[23] was applied to establish VH and VL gene
utilization and heavy-chain CDR composition of the scFv
antibodies (Additional file 1). The VH domains in scFv 2G9
and 4G5 and 2E10 are VH4, while 3E11 and 3D8 are VH3.
Light chains were κ except for the 3E11. The binding
affinity for rhGPC3 was established by ELISA at two con-
centrations of rhGPC3 protein and repeated, with affinityle scFvs. scFv cDNA amplified from the enriched yeast population was
ed to secrete scFvs with 2% galactose. Culture supernatant (5 ul) were
proximately 80% of yeast transformants produced soluble scFv. B.
e coated with hGPC3-GST and GST protein. scFvs were incubated in
quantification of binding. Each scFv was tested in parallel for binding
were screened for binding to full-length hGPC3 protein expressed by
58. The remainder of scFv were isolated using the truncated rhGPC3-
Figure 4 Affinity assessment of scFvs. A. Immunoblot analysis of binding of scFv to rhGPC3. The antigens including rhGPC3 and GST protein
were spotted onto cellulose membrane (10 ng/each). After the blocking step the membrane were incubated with the scFvs antibody in room
temperature for 1 h. The binding of scFv to antigen was detected by incubation with mouse anti-V5 mAb following by infrared dye IR680-labeled
anti-mouse antibodies. PBS was used as negative control. B. Direct ELISA for affinity determination of scFv 3E11. Two different concentration of
rhGPC3 protein (0.5 and 1.0 ug/ml) were coated and incubated with serial diluted scFv 3E11. For detection, mouse-sourced anti-V5 mAb following
HRP-conjugated anti-mouse antibody and SureBlue substrate (measured at 450 nm) were used. C. EC50 values for 5 candidate scFvs determined
by direct ELISA are shown. Assays were performed twice separately for each scFv.
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tration (EC50) using a non-linear regression curve-fit
algorithm. The EC50 value of scFvs range from 3nM to
105nM. For scFv 3E11, the comparable affinities were
measured to be 14nM at the concentration of 1 ug/ml
and be 11nM of 0.5 ug/ml rhGPC3 protein (Figure 4B
and 4C).
scFv binding to native hGPC3 protein specifically on
human cell surface on glypican-3-expressing cell lines
We further test scFv binding to naturally expressed surface
hGPC3. Multiple scFv including 3E11, 2G9 and 3D8 were
complexed with anti-V5 APC and incubated with HepG2
(glypican-3+), 293T (glypican-3-negative) or Hs578T
(glypican-3-negative) cell lines, which were then washed
and assessed by flow cytometry. As shown in Figure 5B, all
three scFv exhibited a range of binding affinity to
endogenous surface-expressed hGPC3 on HepG2, while no
binding was found on 293T or Hs578T cells. Many add-
itional scFv candidates failed to bind naturally expressed
GPC3 including 4C5 and 5G5 among others (data not
shown). Binding was also confirmed by immunofluores-
cence microscopy (Figure 5C) using HepG2.tdTomato and
Hs578t.tdTomato cells. The transduction of tdTomatoRed
protein did not alter GPC3 expression in HepG2 cells (data
not shown). scFv-3E11, 2G9 and 3D8 showed intense
membrane immunofluorescence staining with a significantfraction of viable HepG2.tdTomato cells. All these data
suggested that these three scFvs specifically recognize nat-
urally expressed hGPC3 protein and absence of cross-re-
activity to other surface proteoglycans.Validation of scFvs’ specificities in RNAi-based cell binding
To further confirm the specificity for scFv binding to
hGPC3, we utilized GPC3-shRNA transduced HepG2
cells. Silencing was confirmed by co-expressing a plasmid
encoding myc-tagged hGPC3(AA 368–551) with three
shRNA candidate vectors in 293T cells. sh57 showed the
best silencing efficiency, reducing hGPC3 protein levels up
to 80% compared to the scrambled control (Figure 6A).
sh57 was then retrovirally transduced into HepG2 cells in
a GFP-expressing vector to generate HepG2.sh57 stable
cell line. HepG2.sh57 markedly reduced surface glypican-3
expression by approximately 75% reduction of MFI when
detected with 1G12 (Figure 6B-C). scFvs including 3E11,
2G9, 3D8, 2E10 and 4G5 were incubated with HepG2 and
HepG2.sh57 cells, respectively, and detected by APC-
labeled anti-V5 mAb. As shown in Figure 6D, significant
reduction of binding between HepG2 and HepG2.sh57
cells was observed with scFv-3E11, 2G9 and 3D8, while
the staining with scFv-2E10 and 4G5 had no detectable
differences (data not shown). These findings were con-
firmed by immunofluorescence staining in which a 1:1
Figure 5 scFvs specifically bind glypican-3-expressing cell lines. A. Western blot confirmation of expression of glypican-3 in HepG2 and 293T.
GPC3, knockdown in HepG2.sh57, and absence of expression in parental 293T and Hs578t. 1G12 antibody used for detection. B. Detection of
hGPC3 expression on HepG2 and Hs578T cells by immunofluorescent microscopy using commercial 1G12 anti-GPC3 mAb followed by anti-mouse
Alexa Fluor 488. C. Binding of scFvs to HepG2 and Hs578T cells by flow cytometry using indicated scFv or 1G12 mAb followed by either APC-
conjugated anti-V5 mAb or anti-mouse IR680 (for 1G12 only). Cells incubated with isotype antibody were used as negative control (grey area). D.
Immunofluorescence of scFvs (detected with anti-V5 Alexa Fluor 488 (green)) detected on HepG2.tdTomato (red).
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scFv (Figure 6E). Cell membrane staining by scFvs was
profoundly reduced in HepG2.sh57 relative to wild-type
HepG2 cells.
Glypican-3-specific scFv are not cytostatic
To determine if scFv binding to membrane-associated
glypican-3 alters cellular proliferation, we performed a
standard MTT assay after validation of the accuracy ofFigure 6 scFv validation by HepG2 and HepG2-shRNA cell lines. A. Scr
with shRNA-harboring pSIREN-ZsGreen vector and hGPC3368-551-expressing
Western blot using anti-myc antibody. GAPDH was used as control. B-C. Lo
expression was established in HepG2 cell line via retroviral transduction. hG
antibody (1G12) followed by anti-mouse APC. Unstained HepG2 cells (grey
(green line), and HepG2-sh57 (red line) are shown. The mean fluorescent in
calculated in C. D. scFv binding to surface of HepG2 (black line) and HepG2
with the indicated scFvs and detected by APC-conjugated anti-V5 mAb. E.
(GFP-negative) and HepG2.sh57 (GFP-positive) cells. The cellular mixture of
were stained with the indicated scFv and detected by anti-V5 mAb followeMTT to measure proliferation of HepG2 cells (Figure 7A).
As shown in Figure 7B, no positive or negative impact on
proliferation of the glypican-3-expressing HepG2 cell line
was detected with any scFv at high concentration (1 ug/ml).
Discussion
Therapeutic options for hepatocellular carcinoma (HCC)
remain limited particularly in advanced stages. Immuno-
therapy with NK- or T-cell augmenting therapies to dateeening of shRNAs for hGPC3 silencing. HEK 293 cells were transfected
plasmid. Expression of myc-tagged hGPC3368-551 was assessed by
wer expression of hGPC3 in HepG2-sh57 expressing cells. Stable sh57
PC3 expression in these cells was detected by FACS using anti-GPC3
area), mouse isotype control-stained HepG2 (black line), HepG2 cells
tensity of 3E11 scFv binding in HepG2 and HepG2-sh57 cells were
-sh57 (grey area) cells demonstrated by FACS. Cells were incubated
Differential confocal immunofluorescence staining of scFv with HepG2
HepG2 and HepG2.sh57 (1:1) were cultured in slice chamber. Cells
d by anti-mouse Alexa Fluor 546 secondary antibody.
Figure 7 Lack of impact of scFv on proliferation of HepG2 cells. A. Validation of MTT assay as measurement of growth of HepG2. HepG2 and
HepG2.sh57 cell lines were grown for 4 days in culture. Manual counting with hematocytometer of trypsinized cells correlated strongly with MTT
OD450 (R2 = 0.99). B. Effect of scFv on cell line proliferation. MTT OD450 for HepG2 cultured for 2 or 4 days in the presence or absence of 2E10,
3E11, 3D8, 4G5, and 2G9 at 1 μg/ml showed no evidence of growth inhibition.
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low affinity of endogenous tumor-specific T-cell receptors
and the immunosuppressive milieu of the tumor micro-
environment represent barriers to effectively harnessing
the power of the endogenous immune system to control
cancer. Yeast-derived scFv offer many advantageous
properties for the development of anti-tumor biologics.
scFv are inexpensive to produce, easily modifiable e.g.
biotinylation [28], and facile for subsequent cloning in cis
with diagnostic or effector domains.
Identification of an appropriate tumor–associated antigen
is an obviously essential requirement for scFv development.
Glypican-3 (GPC3), a heparan-sulfate proteoglycan, has
recently been identified as a highly specific, membrane-
associated tumor antigen found in 49-100% of HCC [2-5].
GPC3 is not expressed (or is expressed very focally [29]) in
non-tumorous cirrhotic liver tissue [7,30] and expression of
GPC3 in other normal tissues appears limited [7]. GPC3
modulates the effect of growth factors such as IGF-2,
BMP-7 and FGF-2 on hepatoma cells [11,12] and may
recruit M2 tumor-promoting macrophages to the HCC
microenvironment [13]. Emerging evidence also suggests
that inhibition of glypican-3 function via knockdown
[14,15] or competition [12,16] has a profound negative ef-
fect on HCC proliferation. Expression on the cell surface
makes GPC3 an attractive target for antibody-directed
therapy. Another group has shown that a murine anti-
hGPC3 antibody induces antibody-dependent cytotoxicity
that manifests an anti-tumor effect in a xenograft animal
model of hepatocellular carcinoma [31]; this antibody has
subsequently been humanized [18] and is entering human
clinical trials. Thus, available evidence suggests that
glypican-3 is a rational target for humoral and potentially
chimeric immunotherapy for HCC.
In this study, we utilized the paired display/secretion
yeast system to isolate five candidate scFv with affinity in
the range from 5.0 – 110.9 nM that each demonstrate
specificity for binding the surface of glypican-3-expressingcell lines. scFv binding was significantly reduced after
specific knockdown of glypican-3. The paired yeast
display/secretion system minimizes post-translational and
conformational changes in the conversion from displayed
to soluble scFvs, a property that allows for consistency
during the high throughput screening and validation
process [20]. scFv specificity to the naturally processed
glypican-3 protein at physiological conditions was
critical given complex post-translational modifications of
glypican-3. We utilized increasingly physiological screen-
ing criteria to select scFv candidates for further evaluation.
Dramatic differences of scFv binding between wild-type
and glypican-3-knockdown HepG2 in cell culture condi-
tions confirmed not only the specificity of scFv binding
but also the capacity to bind to naturally-processed cell
surface glypican-3 in situ. In separate work, we are
currently validating a chimeric antigen receptor to redirect
T-cells against glypican-3-expressing targets using our
3E11 scFv.
Not surprisingly, scFv had no direct positive or negative
impact on cellular proliferation unlike that demonstrated
by soluble glypican-3 [12]. The relatively small size of scFv
(27 kD) makes competitive inhibition of growth factor
binding unlikely. We did not include agonism or antago-
nism in our screening strategy, and thus lack of agonist
and antagonistic effect is not unexpected. Conjugation
of our scFv to cellular cytotoxins will be explored as a
potential therapeutic application of the scFv technology.
Conclusion
Glypican-3 is a rational target in hepatocellular carcinoma
for antibody-based therapy. Utilizing a recently described
paired display/secretory yeast library to isolate human-
derived scFv against glypican-3, five unique scFv with
affinity ranging from 5.0-110.9nM were identified. Each
scFv in vitro demonstrated strong surface binding to
glypican-3-expressing cell lines that was attenuated by
shRNA knockdown, and did not bind glypican-3-
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the in vitro and in vivo application of these scFv in
chimeric antigen receptor technology for hepatocellular
carcinoma.
Methods
Cell lines and media
Cell lines of 293T (American Type Culture Collection,
Manassas VA), HepG2 (ATCC), Hep3B (obtained from the
Penn Center for Molecular Studies in Digestive and Liver
Disease) and GP2-293 cells (Clontech, Mountain View,
CA) were maintained in Dulbecco’s modified essential
medium DMEM (Invitrogen, Carlsbad, CA) with 10% fetal
bovine serum (Sigma, St. Louis MO). HepG2.tdTomato
were generated via stable transfection of parental HepG2
with a lentiviral vector encoding tdTomatoRed (a gift from
Dr. Carl June) and purified by flow cytometry. 293T.GPC3
were generated by cloning full-length human GPC3
cDNA (NM_004484) into pDisplay (Invitrogen) XmaI
and SacII sites using the following forward (5′
CCCGGGGCCACCTGTCACCAAGTCCG 3′) and
reverse primer (5′ CCGCGG GTGCACCAGGAAGAA-
GAAGCAC 3′).
Inducible expression and purification of truncated hGPC3
protein
The full-length cDNA of human glypican-3 (NM_004484)
was amplified from a human cDNA library using the
following forward primer (5′ ATGGCCGGGACCGTGC
GCACC 3′) and reverse primer (5′ TCAGTGCACCAG
GAAGAAGAAGCA 3′). A 594 bp DNA fragment
corresponding to the region of nt1277-1871, which trans-
lates a truncated fragment of hGPC3 (aa 368–548) be-
tween the CRD cleavage site and putative transmembrane
domain, was cloned into the prokaryotic expression vector
pGEX-4T using SalI and EcoRI restriction sites (forward
primer: 5′CCG GAA TTC GAC AAG AAA GTA TTA
AAA GTT GCT CA 3′ and reverse primer: 5’ ACG CGT
CGA CGG TGC TTA TCT CGT TGT CCT TC-3′) to
generate a plasmid encoding a truncated hGPC3-GST
recombinant fusion protein under the control of an IPTG-
inducible tac promoter. The plasmid was transformed into
E. coli BL21-CodonPlus (DE3)-RIPL (Stratagene, Santa
Clara CA), grown in fresh 2YT medium, and induced by
1 mM IPTG at 25c for 6 h. Bacterial cells were collected
by centrifugation and lysed by sonication in presence
of 1% sarkosyl and 2% Triton X-100. The lysate was
incubated with Glutathione Sepharose 4B beads (GE
healthcare, Piscataway NJ) at 4c for 4 h, washed, and then
eluted 50 mM Tris–HCl buffer (pH 7.4) containing
20 mM reduced glutathione. The recovery of the GST and
GPC3-GST fusion protein was confirmed by Coomassie
Blue staining. The trhGPC3-GST, GST, and a commercially
custom synthesized 29mer GPC3 peptide (aa 530–558,Proimmune Oxford UK) were biotinylated using NHS
Biotinylation kit (Pierce, Rockford IL).
Selection of hGPC3-reactive scFvs by screening paired
yeast-display/secretory scFv library
The paired yeast-display/secretory scFv library has pre-
viously been described [10], and was screened using
existing methodology with minor modifications. Briefly
the yeast display library was grown in SD-CAA (2% raf-
finose, 0.67% yeast nitrogen base, and 0.5% casamino
acids) at 30c to an Å600 of ~5. Surface display of scFv
was induced by re-inoculating yeast at an Å600 of 0.5
in SGRD-CAA (SD-CAA+ 2% galactose) and grown at
20c for 16-36 h. scFv expression by yeast was con-
firmed by flow cytometry using anti-c-myc mouse mAb
(9E10, Santa Cruz biotechnology) and goat anti-mouse
Fab Alexa Fluor 488 (AF488, Invitrogen, Carlsbad CA).
Two rounds of magnetic bead-based selection were
performed as follows: 1x109 induced yeast-display scFv
in 500 ul PBE buffer (PBS + 0.5% EDTA) were incu-
bated with biotinylated 29mer GPC3 peptide (100nM)
or biotinylated rhGPC3-GST (100 ng/ml) at 25c for
30 min then on ice for 10 min. The rhGPC3-reactive
yeast-display scFv were enriched by magnetically sort-
ing over an LS column (Miltenyi Biotec, Auburn, CA).
When screening with rhGPC3-GST protein, GST-react-
ive yeast-display scFv were depleted over an LS column
after incubation of yeast-display scFv with biotinylated
GST and streptavidin microbeads. Three rounds of flow
cytometry-based sorting were performed with gradually
decreasing concentration of target antigen as follows:
yeast cells were stained with mouse anti-c-myc mAb
(1:200), anti-mouse IgG1 AF488, biotinylated antigen
(rhGPC3 protein at 40 ng/ml in 1st round, 20 ng/ml in
2nd round, and 10 ng/ml in 3rd round), and either
streptavidin-PE (1st and 2nd round, Invitrogen) or neu-
travidin-PE (3rd round, Invitrogen). AF488+ and PE+
double positive yeast were selected and recovered in 96
well plates containing SD-CAA. In all FACS sorts, condi-
tions without antigen, with an irrelevant biotinylated anti-
gen, or with biotinylated GST were included.
High throughput purification of secreted scFvs
scFv cDNA were extracted from the enriched yeast popula-
tion after the 3rd round of flow sorting, amplified by PCR
(forward primer: 5′-GGT TCTGGTGGTGGAGGTTCTG
GTGGTGGTGGATCTG-3; reverse 5′-GAGACCGAGGAG
AGGGTTAGGGATAGGCTTACCGTCGACCAAGTCTT
CTTCAGAATA AGCTT-3′), purified using MiniElute kit
(Qiagen, Valencia CA), and then co-transformed with
100 ng of linearized p416-BCCP vector into YVH10 cells.
Transformed yeast were plated on Trp+SD-CAA dishes,
from which approximately six hundred colonies were
transferred to growth medium in deep 96-well plates
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scFv for up to 72 h. High throughput purification of scFv
was performed as previously described by Bergan et al. [32].ELISA and measurement scFv affinity by ELISA
For screening of scFv affinity, Nunc Maxisorb plates were
pre-coated target antigen or control at the indicated con-
centration in carbonate-bicarbonate buffer on overnight at
4c. Target antigens included: 1) GPC3550-558 peptide with
media control; 2) rhGPC3.GST expressed in E. coli with
GST as control; and 3) rhGPC31-559. His expressed in
murine myeloma cell line (R&D Systems, Minneapolis
MN) with media control After three washing steps with
PBS/0.1% Tween-20 (PBST), 300 ul per well of blocking
solution (2% milk in PBS pH 7) was added for 2 h at room
temperature then washed three times with PBST. Candi-
date scFv starting at 100 ug/ml were added, incubated for
1 h at room temperature followed by three washing steps
with PBST. scFv binding was detected by adding anti-V5
HRP (Invitrogen), washing x 4 with PBST, washing x 1
with PBS, then adding 50 ul/well of TMB peroxidase
substrate (KPL, Gaithersburg MD) plus peroxidase
substrate solution B at 1:1 ratio, then stopping the reaction
with 50 ul 0.5 M H2SO4. OD450 was measured using a
BioRad 680 microplate reader. For determination of
functional affinity, ELISA was performed as above with
plates coated with rhGPC3.GST at two dilutions and with
scFv added at serial dilutions starting at 110 ug/ml. Half-
maximal binding concentration (EC50) was calculated
with non-linear regression curve fit algorithm the software
program PRISM (GraphPad Software, San Diego, CA).
rhGPC3 expressed in murine myeloma cell line was
commercially obtained (R&D Systems, Minneapolis MN).Flow cytometry
Detection of scFv binding to cell lines was detected with
anti-V5 mAb (AbD Serotec, Raleigh, NC). Anti-hGPC3
mAb (1G12, Biomosaics Inc., Burlington, VT) was utilized
as a positive control. scFv were premixed with anti-V5
APC mAb (AbD Serotec) at a molar ratio of 1:1 for
30 min at RT. scFv-anti-V5 complexes were then
incubated with target cell lines for 30 min at 37c. Cells
were acquired on a FACSCanto (Becton Dickinson,
San Jose CA) and analyzed using FlowJo (Treestar,
Ashland, OR).Confocal immunofluorescence
Target cell lines cultured on 0.2 μm coverslips (Nunc,
Rochester, NY) were fixed and stained with indicated
scFv-V5 APC complex. Image acquisition was per-
formed on a Fluoview 10 confocal laser microscope
(Olympus).Western and dot blot
Cell lysates were separated by SDS-PAGE gel and
transferred to polyvinylidene difluoride membranes. In dot
blot, purified protein (10 ng) was spotted on PVDF
membrane. Membranes were blotted with primary Abs
followed by incubation with infrared dye IR680-labeled
secondary antibodies and quantified with LI-COR Odyssey
software.Glypican-3 knockdown
hGPC3-specific short hairpin RNAs (shRNAs) were
prepared in the pSIREN-retroQ-zsGreen retroviral vector
by using knockout RNAi systems according to the
manufacturer’s instruction (Clontech). Three pairs of 21
nucleotide oligonucleotides, named sh56, sh57, and sh58
as well as a LacZ (negative control), were predicted
according to Ambion Silencer Select software, annealed
and sub-cloned into pSIREN-retroQ-zsGreen at the
BamHI and EcoRI sites. The RNA targeting sequence of
these three shRNAs are (sh56: 5′-GCCAAATTATTCTCC
TATGTT-3′; sh57: 5′-GCCAATATAGATCTGCTTATT
-3′; sh58: 5′- GCTCAAGAAAGATGGAAGAAA-3′). For
testing hairpin silencing, myc-tagged hGPC3(AA 368–551)
was cloned into the pDisplay plasmid. Plasmids expressing
shRNA and hGPC3.myc plasmids were co-transfected into
HEK 293 cells (3:1 ratio, hairpin to target), and cells
were lysed after 48 h. hGPC3.myc levels were quantified
by Western blot using anti-c-myc mAb. Pseudotyped
retrovirus encoding shRNA were then produced. Briefly,
GP2-293 cells were seeded in 10 cm cell culture dishes
12 h prior to transfection. At 50% density, cells were
transfected with 10 ug pSIREN-shRNA plasmid and 5 ug
pVSV-G (Clontech) for pseudotyping using the calcium
phosphate transfection method. On day 2 and day 3 after
transfection, media containing retroviral particles
were collected. Particles were concentrated 100-fold by
ultracentrifugation. To infect cells, 10 ul of concentrated
virus stock were added into 1 ×106 HepG2 cells in
presence of polybrene (4 ug/ml). Transduced cells were
isolated by FACS sorting of eGFP+ cells and maintained
as stable cell lines.MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay
We performed a standard MTT assay using the CellTiter
96W Non-Radioactive Cell Proliferation Assay (Promega
Corporation, Madison WI) according to manufacturer’s
instructions. HepG2 and HepG2.sh57 cells were plated
at a density of 5 × 103 cells/well in triplicate in a 96-well
plate and incubated for 2–4 days as indicated. Optical
density was measured at 570 nm. Trypisinized cells were
manually counted by hematocytometer in validation
experiments.
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